Clinical Trials
3 trialsNCT01042379 2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT03310957 2025-12-12
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Seagen Inc.
Phase 1/2 Completed
NCT01969643 2023-03-07
A Safety Study of SGN-LIV1A in Breast Cancer Patients
Seagen Inc.
Phase 1 Completed